利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.063 秒)

    B7-2: a CTLA4/CD28 ligand
    7.
    发明授权
    B7-2: a CTLA4/CD28 ligand 失效
    B7-2：CTLA4 / CD28配体

    公开(公告)号：US5942607A

    公开(公告)日：1999-08-24

    申请号：US101624

    申请日：1993-07-26

    申请人： Gordon J. Freeman ,  Lee M. Nadler ,  Gary S. Gray

    发明人： Gordon J. Freeman ,  Lee M. Nadler ,  Gary S. Gray

    IPC分类号： A61K38/00 ,  C07K14/705 ,  C07K16/28 ,  C12N15/12 ,  C12N15/85 ,  C07H21/00

    CPC分类号： C12N15/8509 ,  C07K14/70532 ,  C07K16/2827 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2267/03 ,  A01K2267/0381 ,  A61K38/00 ,  C07K2317/73 ,  C07K2319/30

    摘要： Isolated nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the isolated nucleic acid has a sequence which encodes a B lymphocyte activation antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in FIG. 8, SEQ ID NO: 1. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn can direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen.

    摘要翻译： 公开了分泌的编码新型CTLA4 / CD28配体的核酸，其共同刺激T细胞活化。 在一个实施方案中，分离的核酸具有编码B淋巴细胞活化抗原B7-2的序列。 优选地，核酸是包含图1所示的核苷酸序列的至少一部分的DNA分子。 8，SEQ ID NO：1。本发明的核酸序列可以整合到各种表达载体中，其又可以指导各种宿主，特别是真核细胞（例如哺乳动物和哺乳动物）中相应的蛋白质或肽的合成 昆虫细胞培养。 还公开了转化以产生由本发明的核酸序列编码的蛋白质或肽的宿主细胞和包含至少一部分新型B淋巴细胞抗原的分离的蛋白质和肽。

    Modulation of TIM receptor activity in combination with cytoreductive therapy
    8.
    发明授权
    Modulation of TIM receptor activity in combination with cytoreductive therapy 有权
    调节TIM受体活性与细胞减灭疗法联合应用

    公开(公告)号：US08709412B2

    公开(公告)日：2014-04-29

    申请号：US13176651

    申请日：2011-07-05

    申请人： Jennifer Jones ,  Rosemarie Dekruyff ,  Dale T. Umetsu ,  Gordon J. Freeman ,  Susan Jane Knox

    发明人： Jennifer Jones ,  Rosemarie Dekruyff ,  Dale T. Umetsu ,  Gordon J. Freeman ,  Susan Jane Knox

    IPC分类号： A61K39/395

    CPC分类号： C07K16/30 ,  A61K39/0011 ,  C07K14/70503 ,  C07K2317/75

    摘要： A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

    摘要翻译： 提供了与调节免疫功能和细胞存活相关的遗传基因座和相应的蛋白质家族。 这些基因编码具有保守IgV和粘蛋白结构域的细胞表面分子。 包含TIM家族的基因座与遗传上与免疫功能障碍有关，包括哮喘。 此外，TIM基因家族位于人类染色体5的区域，通常在恶性肿瘤和骨髓增生异常综合征中缺失。 基因序列中的多态性与气道高反应性和过敏性炎症的发生以及IL-4和IL-13的T细胞产生有关。 蛋白质包括人类甲型肝炎细胞受体hHAVcr-1。

    Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof
    9.
    发明授权
    Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof 有权
    调节B7-1多肽与PD-L1的相互作用的试剂及其使用方法

    公开(公告)号：US07722868B2

    公开(公告)日：2010-05-25

    申请号：US11501392

    申请日：2006-08-09

    申请人： Gordon J. Freeman ,  Arlene H. Sharpe ,  Janet Buhlman ,  Didier Mandelbrot

    发明人： Gordon J. Freeman ,  Arlene H. Sharpe ,  Janet Buhlman ,  Didier Mandelbrot

    IPC分类号： A61K39/395

    CPC分类号： G01N33/6854 ,  A61K38/1709 ,  G01N33/505 ,  G01N33/6872 ,  G01N2333/70532 ,  G01N2500/02

    摘要： Disclosed are methods for modulating an immune response including a method for inhibiting the interaction between a B7 polypeptide and a PD-1 ligand, the method comprising contacting an immune cell bearing a PD-1 ligand, or an immune cell bearing a B7 polypeptide, with an agent that inhibits the interaction between the PD-1 ligand and the B7 polypeptide. Such agents may be an anti-PD-1 ligand antibody or a small molecule. Also disclosed is a method for modulating an immune response comprising contacting an immune cell bearing the PD-1 ligand, or an immune cell bearing the PD-1 polypeptide, with an agent that inhibits interactions between the PD-1 ligand and the PD-1 polypeptide, without inhibiting interactions between the PD-1 ligand and a B7 polypeptide, to thereby modulate an immune response. The agent may be an anti-PD-1 ligand antibody or a small molecule.

    摘要翻译： 公开了用于调节免疫应答的方法，包括抑制B7多肽和PD-1配体之间的相互作用的方法，所述方法包括使带有PD-1配体或带有B7多肽的免疫细胞的免疫细胞与 抑制PD-1配体和B7多肽之间的相互作用的试剂。 这样的试剂可以是抗PD-1配体抗体或小分子。 还公开了一种用于调节免疫应答的方法，包括将携带PD-1配体或携带PD-1多肽的免疫细胞的免疫细胞与抑制PD-1配体和PD-1之间的相互作用的试剂接触 多肽，而不抑制PD-1配体和B7多肽之间的相互作用，从而调节免疫应答。 该试剂可以是抗PD-1配体抗体或小分子。